159681-66-0 Usage
Description
Ulipristal acetate InterMediate, also known as N-Desmethyl Ulipristal Acetate, is the N-monodemethylated analogue and metabolite of the selective progesterone receptor modulator Ulipristal Acetate (U700810). It is a beige solid that contributes significantly to the antiprogestational activity of its parent compound.
Uses
Used in Pharmaceutical Industry:
Ulipristal acetate InterMediate is used as a pharmaceutical intermediate for the development of medications that modulate progesterone receptor activity. Its primary application is in the enhancement of the antiprogestational activity of its parent compound, Ulipristal Acetate, which has various therapeutic applications, including contraception and treatment of certain gynecological conditions.
Used in Contraceptive Applications:
In the contraceptive industry, Ulipristal acetate InterMediate is used as an active pharmaceutical ingredient for the development of emergency contraceptive pills. Its antiprogestational properties help prevent ovulation, fertilization, and implantation, providing a temporary method of birth control.
Used in Gynecological Treatments:
Ulipristal acetate InterMediate is used as a therapeutic agent for the treatment of gynecological conditions such as endometriosis and uterine fibroids. Its ability to modulate progesterone receptor activity helps alleviate symptoms and reduce the size of endometrial tissue and fibroids, improving the quality of life for patients suffering from these conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 159681-66-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,9,6,8 and 1 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 159681-66:
(8*1)+(7*5)+(6*9)+(5*6)+(4*8)+(3*1)+(2*6)+(1*6)=180
180 % 10 = 0
So 159681-66-0 is a valid CAS Registry Number.
159681-66-0Relevant articles and documents
ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS
-
Page/Page column 133-134, (2021/05/21)
The disclosure relates to anti-cancer compounds which are anti-cancer PARP inhibitors of formula Al, A2, A3 or A4 conjugated by a linker to a steroid, whereby the steroid targets the conjugate to the nucleus, as well as to methods for their preparation and use. (I)
Synthesis of N-desmethyl derivatives of 17α-acetoxy-11β(4-N,N- dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and mifepristone: Substrates for the synthesis of radioligands
Rao, Pemmaraju N.,Acosta, C. Kirk,Cessac, James W.,Bahr, Martin L.,Kim, Hyun K.
, p. 205 - 212 (2007/10/03)
The syntheses of N-desmethyl derivatives of CDB-2914 and the mono-N- desmethyl derivative of Mifepristone are described. We also describe the use of the mono-desmethyl derivatives as substrates for the synthesis of N- tritomethyl derivatives of CDB-2914 a
